CEOcast.com Interviewed Atlantic Technology Ventures President & CEO, Frederic Zotos.

Business/Health Editors

NEW YORK--(BW HealthWire)--May 20, 2002

Atlantic Technology Ventures, Inc. (OTC:ATLC.OB- news) President and Chief Executive Officer, Frederic P. Zotos, was interviewed by CEOcast.com a leading on-line financial forum on May 16, 2002.

The interview with Mr. Zotos will be accessible for the next several days at www.ceocast.com.

During the interview, Mr. Zotos discussed the Company's operating results and the development status of its two main clinical projects -- the Avantix (formerly known as "Catarex") surgical device for cataract removal, and CT-3, a synthetic cannabinoid derivative for treating pain and inflammation.

Mr. Zotos reviewed the recently initiated phase II clinical trial evaluating the safety, efficacy and dosing of CT-3 in cases of chronic neuropathic pain. In addition, he explained how the Company is also engaged in pre-clinical testing of CT-3 for several other indications including multiple sclerosis tremors and spasticity, rheumatoid arthritis, opioid synergistic effects and as a topical anti-blister antidote for sulfur-mustard gas exposure.

Comments by Mr. Zotos on the current development status of the Avantix device with reference to the April 2002 edition of Cataract & Refractive Surgery Today that features two articles on the Avantix Endocapsular Vortex Emulsification Technology conclude the interview.

In order to hear this exclusive audio interview on the CEOcast.com website, your computer must be appropriately configured.

About CT-3

CT-3 is a chirally pure, patented synthetic carboxylic derivative of tetrahydrocannabinol (THC-7C). It is a new chemical entity specifically designed to have increased analgesic and anti-inflammatory properties and reduced psychotropic activity compared to the THC parent. Pre-clinical animal studies have shown that CT-3 demonstrates analgesic/anti-inflammatory properties at microgram doses without central nervous system or gastrointestinal side effects.

About Avantix

Avantix is a proprietary surgical instrument system and associated disposable handpieces for cataract removal. Avantix is easier to use and less invasive than currently available cataract removal technologies. It enables a surgeon to remove a cataract in less than 10 minutes through a single, 1.25 millimeter incision versus 25-40 minutes through a 3 to 11mm incision. Avantix is the only technology that functionally preserves the lens capsule intact after surgery. If used in conjunction with liquid polymer lenses currently being developed by several large pharmaceutical companies, Avantix could potentially treat cataracts, refractive error, and the need for reading glasses all at once. There are over 2.5 million refractive surgery operations annually performed in the U.S.

About Atlantic Technology Ventures, Inc.

Atlantic is engaged in the development of biomedical and pharmaceutical products and related technologies. Atlantic's strategy is to identify nascent medical products and technologies that have the potential to address unmet market needs, rapidly develop these through a definitive proof-of-principle, then partner, license or sell them to realize significant revenue. Atlantic currently has ownership interest in Avantix (formerly known as "Catarex"), a surgical device for cataract removal, and CT-3, a synthetic cannabinoid derivative for treating pain and inflammation.

Safe Harbor Statement

Cautionary statement under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: This press release contains certain forward-looking statements that relate to future scientific, business and financial performance. These statements are only predictions and are subject to a number of risks and uncertainties that may cause the actual events or results to differ from those discussed or implied in these statements. These risks and uncertainties include competition from other manufacturers of related technologies, the unavailability of any necessary intellectual property rights possessed by third parties, and certain of those risks described in Atlantic's most recent report on Form 10-KSB with the Securities and Exchange Commission.